Cangrelor shows promise for PCI in some patients

03/11/2013 | MedPage Today (free registration) · Forbes

The antiplatelet drug cangrelor bested clopidogrel in the CHAMPION PHOENIX trial, which found fewer ischemic complications when cangrelor was used in percutaneous coronary intervention. The results were presented at the American College of Cardiology meeting. However, SCAI fellow Dr. Ajay Kirtane of Columbia University Medical Center warned against extrapolating the findings. "I think it really depends on the patient population. I don't think you can extrapolate these data to patients that get preloading," said Kirtane, who noted that in some clinical settings, the new drug could offer opportunities for cost savings.

View Full Article in:

MedPage Today (free registration) · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT